학술논문
First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17
Document Type
Article
Author
Source
In European Journal of Cancer March 2024 200
Subject
Language
ISSN
0959-8049